Clinical trials: Keratoconjunctivitis
Atopic Keratoconjunctivitis
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
This is a multi-center, double-masked, randomized, placebo-controlled, parallel-group, efficacy, safety, and tolerability study evaluating the efficacy of Dupilumab in the treatment of signs and symptoms of atopic…
- Trial name
- NCT04296864
- Testing
- Dupilumab
- Where
- 20 sites in United States
- Volunteers
- 42 people
- Sponsor
- Andover Eye Associates
Keratoconjunctivitis Sicca, Dry Eye Disease
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye.
- Trial name
- OPUS-1 (NCT01421498)
- Testing
- Lifitegrast
- Where
- 13 sites in United States
- Volunteers
- 588 people
- Sponsor
- Shire
Keratoconjunctivitis Sicca
A Study Of Tasocitinib In Dry Eye Subjects
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease.
- Trial name
- NCT01226680
- Testing
- Tasocitinib, vehicle for Tasocitinib
- Sponsor
- Pfizer
Dry Eye Syndrome
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- VISTA-2 (NCT04206020)
- Testing
- SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
- Where
- 4 sites in United States
- Volunteers
- 610 people
- Sponsor
- Mitotech, SA
Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.
- Conditions
- Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis
- Trial name
- KRONOS (NCT03379311)
- Testing
- AK002
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allakos Inc.
Dry Eye Syndrome
Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye
The purpose of this study is to compare the safety and efficacy of RX-10045 to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT00799552
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- Resolvyx Pharmaceuticals, Inc
Dry Eye Disease
Effect of Cequa™ in Subjects With Dry Eye Disease
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
- Trial name
- NCT04357795
- Testing
- CequaTM (Cyclosporine 0.09%) ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 135 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Keratoconjunctivitis Sicca
Effect of Controlled Adverse Environment (CAE) on Tear Film Stability
The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.
- Trial name
- NCT01547936
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ORA, Inc.
Keratoconjunctivitis Sicca, Dry Eye Disease
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry…
- Trial name
- NCT02254265
- Testing
- OTX-101 0.05%, OTX-101 0.09%, Vehicle
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Dry Eye Disease (DED), Keratoconjunctivitis Sicca
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
- Trial name
- NCT07078955
- Testing
- BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06%
- Where
- Taiwan
- Volunteers
- 99 people
- Sponsor
- BRIM Biotechnology Inc.
Dry Eye, Keratoconjunctivitis Sicca
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
- Trial name
- NCT05918406
- Testing
- Nasal Guide
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Oyster Point Pharma, Inc.
Keratoconjunctivitis Sicca, Dry Eye
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
- Trial name
- NCT03925727
- Testing
- Tavilermide ophthalmic solution
- Where
- 22 sites in United States
- Volunteers
- 623 people
- Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
Keratoconjunctivitis Sicca
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease.
- Trial name
- NCT00717418
- Testing
- cyclosporine ophthalmic emulsion 0.05%, artificial tears
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Allergan
Acute Infectious Keratoconjunctivitis
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK).
- Trial name
- NCT05636228
- Testing
- INV-102, Vehicle
- Where
- 12 sites in United States, Thailand
- Volunteers
- 93 people
- Sponsor
- Invirsa, Inc.
Keratoconjunctivitis Sicca
A 1-Year Study in Multiple Clinics Testing Rebamipide Eye Drops for Dry Eye Compared With a Placebo
The purpose of this study is to determine the potential safety and effectiveness of rebamipide eye drops, an investigational eye drop being developed for the treatment of keratoconjunctivitis sicca (dry eye).
- Trial name
- NCT00201981
- Testing
- Rebamipide 1%, Rebamipide 2%
- Where
- 63 sites in United States
- Volunteers
- 755 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Viral Conjunctivitis
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
- Trial name
- NCT01977443
- Testing
- APD-209 Eye drops
- Where
- 10 sites in Germany, Poland and 1 more
- Volunteers
- 47 people
- Sponsor
- Adenovir Pharma AB
Keratoconjunctivitis Sicca
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%) ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS, dry eye syndrome) patients.
- Trial name
- NCT00128245
- Testing
- Pimecrolimus, Vehicle
- Where
- United States
- Volunteers
- 440 people
- Sponsor
- Novartis
Keratoconjunctivitis Sicca
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
This study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (Lotemax®) gel 0.5 percent (%) administered twice daily (BID) with or without cyclosporine…
- Trial name
- NCT01817582
- Testing
- Lotemax, Restasis, Soothe® Lubricant Eye Drops
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis, Ocular Surface Disease
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).
- Trial name
- NCT03769454
- Testing
- PP-001
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Panoptes Pharma GmbH
Dry Eye Syndromes, Keratoconjunctivitis Sicca
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.
- Trial name
- NCT02117687
- Testing
- carboxymethylcellulose 0.5%/glycerin 0.9%, sodium hyaluronate 0.18%
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 80 people
- Sponsor
- Allergan